Pharvaris N.V.

NASDAQ:PHVS

Biotechnology

Healthcare
$31.55 -1.93%

-$0.64 today

Market cap
$2.21B
Beta
-2.33
P/E (TTM)
-11.0
EPS (TTM)
-$2.59
52W Low $16.72High $34.41

Volume 0.39M

Average 0.31M

PHVS Income Before Tax

Profit after all operating and non-operating items but before income tax.

Pharvaris N.V.NASDAQ: PHVS

Income Before Tax · Q3 FY2026 · quarter ended Sep 2026

Income before tax remains negative

Q3 FY2026 income before tax was -€47.2M, compared with -€37.32M a year earlier. Trailing-twelve-month income before tax was -€179.08M.

Context

  • Income before tax grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -€47.2M or moves back toward the trailing-twelve-month quarterly average of -€44.77M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-€47.2M+0.1% QoQ
Last fiscal yearDec 2025
-€173.71M-31.2% YoY
LTMSep 2026
-€179.08M-8.9% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.5%——
1 year-31.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

EUR · from the income statement

Latest · FY2025
(173.71M) EUR
Year-over-year change
-31.2%

Income Before Tax vs competitors

How PHVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.9% is the 3rd highest of 7, against a peer median of -82.2%.
PHVS Competitors
Income Before Tax for PHVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PHARPharming Group N.V.LTM Mar 2026$19.88M USD+643.8%-4.9%5.4%
RLYBRallybio CorporationLTM Mar 2026-$7.82M USD+83.8%—911.1%
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$159.72M USD-80.4%—24.5%
PHVSPharvaris N.V.LTM Sep 2026-€179.08M EUR-8.9%——
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-$381.19M USD-1084.0%—40.5%
VERAVera Therapeutics, Inc.LTM Jun 2026-$401.89M USD-84.1%——
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$131.59B USD-19472.7%+47.8%12.8%
Peer median (excluding PHVS) —-82.2%+21.4%24.5%

Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development35.79M57.38M65.58M98.56M124.48M
Selling, General & Admin18.35M29.34M31.34M47.12M45.34M
Operating Expenses54.14M86.71M96.91M145.69M169.82M
Depreciation & Amortization77.37K152.94K257.55K269.56K418.35K
EBITDA(42.31M)(86.56M)(99.57M)(145.42M)(173.29M)
EBITDA Margin—————
Operating Income(54.14M)(86.71M)(96.91M)(145.69M)(169.82M)
Operating Margin—————
Interest Income2681605.47M0
Interest Expense278.18K16.11K000
Other Income / Expenses11.48M11.06M(2.91M)13.29M(3.89M)
Income Before Tax(42.66M)(75.65M)(99.83M)(132.4M)(173.71M)
Pre-Tax Margin—————
Income Tax Expense70.12K679.09K1.05M1.83M1.99M
Net Income(42.73M)(76.33M)(100.88M)(134.22M)(175.7M)
Net Margin—————
EPS (Basic)(1.41)(2.27)(2.63)(2.48)(2.97)
EPS (Diluted)(1.41)(2.27)(2.63)(2.48)(2.97)
Weighted Avg Shares30.41M33.59M38.39M54.02M59.16M
Weighted Avg Shares (Diluted)30.41M33.59M38.39M54.02M59.16M

Pharvaris N.V.

NASDAQ:PHVS

Intrinsic Alpha fair value

Locked

Current Price

$31.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.